Clarivate (CLVT) to Release Quarterly Earnings on Tuesday

Clarivate (NYSE:CLVT) is projected to post its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of $0.16 per share and revenue of $604.7930 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 9:00 AM ET.

Clarivate Stock Performance

Clarivate stock opened at $1.81 on Tuesday. The business has a 50 day moving average of $2.99 and a 200-day moving average of $3.55. The company has a market capitalization of $1.19 billion, a P/E ratio of -3.17 and a beta of 1.51. Clarivate has a 1 year low of $1.74 and a 1 year high of $5.16. The company has a debt-to-equity ratio of 0.90, a current ratio of 0.87 and a quick ratio of 0.87.

Wall Street Analysts Forecast Growth

CLVT has been the subject of a number of recent research reports. The Goldman Sachs Group downgraded Clarivate from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $4.20 to $3.60 in a report on Thursday, January 8th. Morgan Stanley reissued an “underweight” rating and issued a $3.00 price target (down previously from $5.00) on shares of Clarivate in a research note on Wednesday, December 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Clarivate in a research report on Monday, December 29th. Finally, Wall Street Zen upgraded Clarivate from a “hold” rating to a “buy” rating in a report on Saturday, February 7th. Four investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Clarivate presently has a consensus rating of “Reduce” and a consensus price target of $4.28.

Insider Buying and Selling at Clarivate

In related news, insider Bar Veinstein sold 309,902 shares of the stock in a transaction on Monday, December 1st. The shares were sold at an average price of $3.74, for a total transaction of $1,159,033.48. Following the transaction, the insider directly owned 848,811 shares of the company’s stock, valued at $3,174,553.14. This represents a 26.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 23.18% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Clarivate

Institutional investors and hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada increased its position in Clarivate by 96.2% in the 1st quarter. Royal Bank of Canada now owns 63,630 shares of the company’s stock valued at $250,000 after buying an additional 31,197 shares in the last quarter. AQR Capital Management LLC grew its stake in Clarivate by 37.0% in the first quarter. AQR Capital Management LLC now owns 451,872 shares of the company’s stock valued at $1,749,000 after acquiring an additional 122,099 shares during the period. Millennium Management LLC increased its holdings in shares of Clarivate by 1,420.4% during the first quarter. Millennium Management LLC now owns 1,188,978 shares of the company’s stock valued at $4,673,000 after acquiring an additional 1,110,774 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Clarivate by 15.5% during the first quarter. Goldman Sachs Group Inc. now owns 616,250 shares of the company’s stock worth $2,422,000 after purchasing an additional 82,768 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Clarivate by 13.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,243,683 shares of the company’s stock worth $4,888,000 after purchasing an additional 144,462 shares in the last quarter. Institutional investors own 85.72% of the company’s stock.

About Clarivate

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.